Position in EXEL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$26,025,500
+$11,584,180 QoQ
Shares Held
478,322
+42.1% QoQ
Ownership
0.193%
of shares outstanding
% of Portfolio
0.15%
of 13F equity value
Holder Rank
#73
of 756 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 99%
Shared 0%
None 1%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Driehaus Capital Management LLC holds $3,707,249,767 across 60 Biotechnology names. EXEL ranks #31 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DFTX |
Definium Therapeutics, Inc.
|
6,845,276 | $322,001,783 | |
| 2 | PRAX |
Praxis Precision Medicines, Inc.
|
959,048 | $321,079,679 | |
| 3 | XENE |
Xenon Pharmaceuticals Inc.
|
4,418,557 | $266,704,100 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
2,799,166 | $248,509,957 | |
| 5 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
6,463,551 | $241,866,078 | |
| 6 | APGE |
Apogee Therapeutics, Inc.
|
1,740,101 | $230,963,605 | |
| 7 | EWTX |
Edgewise Therapeutics, Inc.
|
4,728,623 | $192,123,952 | |
| 8 | SEPN |
Septerna, Inc.
|
4,433,058 | $148,463,112 |
All Filings in EXEL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $26,025,500 | 478,322 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $14,441,320 | 336,706 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $14,785,568 | 337,339 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $13,095,445 | 317,081 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $18,683,528 | 423,855 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $17,128,997 | 463,949 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $11,553,201 | 346,943 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||